Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL201 vs Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma (TAISHAN-303)
NCT07487896Phase 3Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of YL201 in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by MediLink Therapeutics. Primary endpoint: Overall Survival at 36 months. Started Mar 2026; status: recruiting.
02
Drugs
YL201
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07487896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07487896.